4.3 Article

Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis

Journal

JOURNAL OF CYSTIC FIBROSIS
Volume 19, Issue 1, Pages 40-48

Publisher

ELSEVIER
DOI: 10.1016/j.jcf.2019.05.017

Keywords

Neutrophil; Protease; Matrikine; Cystic fibrosis

Funding

  1. National Heart, Lung and Blood Institute [HL077783, HL110950, HL114439, HL126596, HL102371]
  2. Veterans Administration [1101BX001756]
  3. NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London
  4. UAB Health Service Foundation General Endowment Fund

Ask authors/readers for more resources

Background: Proline glycine proline (PGP) is a bioactive fragment of collagen generated by the action of matrix metalloproteinase-9 (MMP-9) and prolylendopeptidase (PE), and capable of eliciting neutrophil chemotaxis and epithelial remodelling. PGP is normally then degraded by leukotriene A(4) hydrolase (LTA(4)H) to limit inflammation and remodelling. This study hypothesized that early and persistent airway neutrophilia in Cystic Fibrosis (CF) may relate to abnormalities in the PGP pathway and sought to understand underlying mechanisms. Methods: Broncho-alveolar lavage (BAL) fluid was obtained from 38 CF (9 newborns and 29 older children) and 24 non-CF children. BAL cell differentials and levels of PGP, MMP-9, PE and LTA(4)H were assessed. Results: Whilst PGP was present in all but one of the older CF children tested, it was absent in non-CF controls and the vast majority of CF newborns. BAL levels of MMP-9 and PE were elevated in older children with CF relative to CF newborns and non-CF controls, correlating with airway neutrophilia and supportive of PGP generation. Furthermore, despite extracellular LTA(4)H commonly being greatly elevated concomitantly with inflammation to promote PGP degradation, this was not the case in CF children, potentially owing to degradation by neutrophil elastase. Conclusions: A striking imbalance between PGP-generating and -degrading enzymes enables PGP accumulation in CF children from early life and potentially supports airway neutrophilia. (C) 2019 The Authors. Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Respiratory System

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosi

Kevin W. Southern, Carlo Castellani, Elise Lammertyn, Alan Smyth, Donald VanDevanter, Silke van Koningsbruggen-Rietschel, Juerg Barben, Amanda Bevan, Edwin Brokaar, Sarah Collins, Gary J. Connett, Thomas W. V. Daniels, Jane Davies, Dimitri Declercq, Silvia Gartner, Andrea Gramegna, Naomi Hamilton, Jenny Hauser, Nataliya Kashirskaya, Laurence Kessler, Jacqueline Lowdon, Halyna Makukh, Clemence Martin, Lisa Morrison, Dilip Nazareth, Jacquelien Noordhoek, Ciaran O'Neill, Elizabeth Owen, Helen Oxley, Karen S. Raraigh, Caroline Raynal, Karen Robinson, Jobst Roehmel, Carsten Schwarz, Isabelle Sermet, Michal Shteinberg, Ian Sinha, Constance Takawira, Peter van Mourik, Marieke Verkleij, Michael D. Waller, Alistair Duff

Summary: Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic variants in the CFTR gene, and CFTR modulators, the first available therapy, have transformed CF management. Interim standards have been produced to guide healthcare professionals in providing variant-specific therapy for CF patients using evidence-based guidance and stakeholder consultation.

JOURNAL OF CYSTIC FIBROSIS (2023)

Article Pediatrics

Migration is not the perfect answer: How the cross-talk error correction for multiple breath nitrogen washout (MBWN2) parameters differs on directly collected vs. legacy data

Christopher Short, Mary Abkir, Sophie Pinnell, Owain Proctor, Clare J. Saunders, Jane C. Davies

Summary: A cross-talk error in commercial MBWN2 software was found, causing over-reading of N-2. Research compared migrated or rerun data to directly collected data, and found significant differences. Caution should be taken when comparing corrected legacy data and 3.3.1 collected data in clinical interpretation.

PEDIATRIC PULMONOLOGY (2023)

Article Microbiology

Diversity and prevalence of type VI secretion system effectors in clinical Pseudomonas aeruginosa isolates

Luca A. Robinson, Alice C. Z. Collins, Ronan A. Murphy, Jane C. Davies, Luke P. Allsopp

Summary: This study conducted a comprehensive bioinformatic analysis of 52 high-quality clinical P. aeruginosa genomes isolated from CF patients. The results showed that the clinical CF isolate genome consists mainly of accessory and unique genes, which may provide strain-specific advantages. The study found genetic variability in some effector/immunity encoding genes and identified the presence of orphan vgrG islands in some isolates. The study also revealed disruption to T6SS genomic loci through transposon, prophage, and mobile genetic element insertions.

FRONTIERS IN MICROBIOLOGY (2023)

Review Immunology

Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?

Sejal Saglani, Laura Yates, Clare M. Lloyd

Summary: Asthma is a disease characterized by type 2 immune dysfunction, with excess secretion of cytokines and eosinophil inflammation. Efforts have been made to develop drugs targeting these immune pathways, but they are not curative and may not fully alleviate key features of the disease. This review discusses the current landscape of therapeutic options targeting type 2 immune cytokines and their efficacy and limitations in both adults and children with asthma.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Editorial Material Immunology

Breathing easy: Dopamine quenches the ILC2 flame

Franz Puttur, Clare M. Lloyd

Summary: In this study, Cao et al. uncover the crucial role of dopamine in inhibiting ILC2 function via metabolic restriction, leading to the improvement of key features in asthma pathogenesis.

IMMUNITY (2023)

Review Immunology

T helper 2 cells in asthma

James A. Harker, Clare M. Lloyd

Summary: Harker and Lloyd review the multifaceted roles of Th2 cells in human asthma, emphasizing the influence of tissue location and disease severity. They also discuss the use of biologic therapies targeting Th2 cells and their cytokines. This review highlights the complex functions of Th2 cells in asthma and how they are affected by tissue location, disease stage, and severity, while also exploring the impact of biologics on asthma and the potential for uncovering new roles for Th2 cells in lung inflammation.

JOURNAL OF EXPERIMENTAL MEDICINE (2023)

Editorial Material Pediatrics

Reply to migration is not the perfect answer: Optimized methodology to assess LCI agreement between corrected legacy multiple breath nitrogen washout data and that directly collected on updated software

Ediane De Queiroz Andrade, Brooke Bailey, Jane C. C. Davies, Renee Jensen, Felix Ratjen, Clare J. J. Saunders, Christopher Short, Paul D. D. Robinson

PEDIATRIC PULMONOLOGY (2023)

Article Infectious Diseases

Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of Pseudomonas aeruginosa Infection

Isaac Martin, Sandra Morales, Eric W. F. W. Alton, Jane C. Davies

Summary: This study found that bacteriophages can be used as adjuncts to treatment for antibiotic refractory infections, and the combination of phages with certain antibiotics may have synergistic effects. Furthermore, phages showed good bactericidal effects against antibiotic resistant Pseudomonas aeruginosa (Pa), which may be relevant to ongoing clinical trials.

ANTIBIOTICS-BASEL (2023)

Article Critical Care Medicine

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial

Paul McNally, Karen Lester, Gavin Stone, Basil Elnazir, Michael Williamson, Des Cox, Barry Linnane, Laura Kirwan, David Rea, Paul O'Regan, Tom Semple, Clare Saunders, Harm A. W. M. Tiddens, Edward McKone, Jane C. Davies

Summary: This study demonstrates that treatment with ETI leads to significant improvements in lung function, lung clearance index, and CT scores in people with cystic fibrosis. The treatment also improves nutrition and quality of life for the patients.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Cell Biology

A conversation on allergy: recognizing the past and looking to the future

Erik Melen, Bart N. Lambrecht, Clare M. Lloyd, Marc E. Rothenberg, Kenji Kabashima, Fabio Luciani, Jonathan M. Coquet, Carole Ober, Martijn C. Nawijn, Thomas Platts-Mills, Erika von Mutius

Summary: Allergy is a group of disorders, affecting over 1 billion people worldwide, which includes asthma, atopic dermatitis, rhinitis, and food allergies. Its incidence has dramatically increased since the start of the 20th century, indicating that both genetics and environmental factors play important roles in its development.

IMMUNOLOGY AND CELL BIOLOGY (2023)

Review Immunology

Early-life respiratory infections and developmental immunity determine lifelong lung health

Clare M. M. Lloyd, Sejal Saglani

Summary: Lloyd and Saglani provide an overview of the immunology of respiratory infections in early life and how it impacts lifelong lung health. Respiratory infections are common in infants and young children, and their effects during this developmental stage can have long-term consequences. The immune system and microbiome in the respiratory tract develop simultaneously, and any disruption to this development can have implications for lung health throughout one's life. The authors emphasize the importance of understanding the molecular mechanisms underlying the interplay between immune and structural cells in the lung and the local microorganisms to mitigate harmful effects and restore lung immune health.

NATURE IMMUNOLOGY (2023)

Article Multidisciplinary Sciences

Lung extracellular matrix modulates KRT5+ basal cell activity in pulmonary fibrosis

Richard J. Hewitt, Franz Puttur, David C. A. Gaboriau, Frederic Fercoq, Maryline Fresquet, William J. Traves, Laura L. Yates, Simone A. Walker, Philip L. Molyneaux, Samuel V. Kemp, Andrew G. Nicholson, Alexandra Rice, Edward Roberts, Rachel Lennon, Leo M. Carlin, Adam J. Byrne, Toby M. Maher, Clare M. Lloyd

Summary: This study reveals the impact of changes in extracellular matrix (ECM) composition secreted by lung fibroblasts on the migration and function of KRT5(+) cells in idiopathic pulmonary fibrosis (IPF), contributing to tissue remodeling in the fibrotic lung.

NATURE COMMUNICATIONS (2023)

Article Critical Care Medicine

Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective

Nicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, Scott H. Donaldson, Isabelle Fajac, Christopher H. Goss, Deepika Polineni, Felix Ratjen, Bradley S. Quon, Edith Zemanick, Scott C. Bell, Jane C. Davies, Manu Jain, Michael W. Konstan, Natanya R. Kerper, Tre LaRosa, Marcus A. Mall, Edward McKone, Kelsie Pearson, Joseph M. Pilewski, Lynne Quittell, Jonathan H. Rayment, Steven M. Rowe, Jennifer L. Taylor-Cousar, George Retsch-Bogart, Damian Downey

Summary: The use of modulator therapies for cystic fibrosis has changed clinical trial strategies, dividing the patient population based on eligibility. The development of nucleic acid-based therapies faces challenges due to limited resources and the inability to conduct placebo-controlled trials. Advancing symptomatic therapies is also difficult in a population already receiving modulator treatment.

LANCET RESPIRATORY MEDICINE (2023)

Article Respiratory System

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting

Paul McNally, Barry Linnane, Michael Williamson, Basil Elnazir, Christopher Short, Clare Saunders, Laura Kirwan, Rea David, Mariette P. C. van de Corput, Harm A. W. M. Tiddens, Jane C. Davies, Des W. Cox

Summary: In this real-world study, the use of LUM/IVA in children aged 6-11 with CF resulted in improvements in air trapping on CT but worsening in bronchiectasis scores, suggesting that LUM/IVA treatment can improve respiratory function but cannot prevent the progression of bronchiectasis.

RESPIRATORY RESEARCH (2023)

Meeting Abstract Biotechnology & Applied Microbiology

Novel Buffer Formulations for Improved Recombinant Lentiviral Vector Stability and In Vivo Delivery to the Murine Lungs

Kamran M. Miah, Mario Chan, Uta Griesenbach, Eric W. F. W. Alton, Stephen C. Hyde, Deborah R. Gill

MOLECULAR THERAPY (2023)

No Data Available